1.
Gynecol Oncol Rep
; 53: 101382, 2024 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38623270
RESUMO
â¢Adverse events of pembrolizumab have been documented, but more severe gastrointestinal effects are not as well described.â¢We report a case of a patient with cervical cancer treated with pembrolizumab who developed small bowel obstruction (SBO)â¢Histological analysis and gastrointestinal workup points to pembrolizumab as likely cause of SBO.